Isreali Nextage Explores Effective Delivery of Psychedelic Compounds

Israel is one of the leading countries for medical cannabis research and has held this title for decades; since the 1960s to be exact. Now, they’re joining efforts to study the benefits of psychedelics in a clinical setting as well.

Of the main areas of focus is using psychoactive compounds to treat clinical depression and other psychiatric disorders. One Israeli company, Nextage Therapeutics, is looking specifically at utilizing ibogaine, along with their own patent delivery system, to better treat people with these conditions.

When it comes to treating psychological disorders and minimizing the risk of side effects, psychedelics are the way of the future. Check out our newsletter, The Delta 8 Weekly, to learn more about these incredible compounds as well as gain access to exclusive deals on flowers, vapes, edibles, and other products.


What are Psychedelics?

Psychedelic drugs are a subset of hallucinogens. They contain psychoactive compounds that are capable of altering a person’s mood, perception, and cognition; sometimes permanently. The active compounds are usually found in nature, like psilocybin or mescaline, but they can also be manmade, like LSD.

Psychedelics are known for causing ‘trips’, which is what the high is referred to. When a person is tripping, they may have altered perceptions of the world around them. Many people believe this is limited to visual and auditory hallucinations, but it can also include feeling, tasting, and smelling things that are not real, as well as a heightened sense of connection and understanding, and greater feelings of introspection.  

The trips that people most commonly associate with these types of the drugs are the ones in which a state of hallucinogenic delirium is reached, but that is not always the case. Many times, it is more of an experience than a trip, and something can be learned and achieved psychologically with every small dose.

The word itself, ‘psychedelics’, was first used in 1957 to recognize substances that were said to open the mind, however, the more accurate term for them is ‘entheogens’. This term was adopted, not necessarily for the sake of being scientific, but rather to allow the sector to operate without all the stigma attached to psychedelics from smear campaigns and restrictive policies throughout history. The term entheogen comes from Greek where it means ‘building the god within’.

Different psychedelics produce different trips. For example, with DMT you can expect a short high lasting less than 1 hour, whereas LSD, psilocybin, and mescaline trips can last up to ten hours. Some hallucinogens are more potent than others, like mushrooms vs acid. The active compounds are different in each drug so there is a lot of variation to the effects that can be felt.  

Some people experience bad trips in which negative, or even scary, hallucinations are experienced, and/or a rapid heartbeat, sweating, nausea, disorientation, and fatigue occur. There is indication that the majority of these symptoms can be controlled through proper dosing. This is why most modern-day, therapeutic users of psychedelics consume the drugs in micro-doses.

Nextage Pharmaceuticals and MindMend

According to Nextage Founder and CEO Abraham Dreazen, “there has been a shift in the last decade. The US Food and Drug Administration, for example, is starting to see quality of life as a factor in evaluating medicine, opening the door to these drugs.”

Earlier this year, Nextage signed a collaboration agreement with industry trailblazer Mindmend, to use their proprietary new technology known as Brain Targeting Liposome System (BTLS) – a delivery system Dreazen claims will “optimize the delivery of drug products based on noribogaine, and ultimately other ibogaine derivatives.”

Ibogaine is a naturally occurring psychoactive substance found in Apocynaceae plant family in Gabon, a small coastal country in central Africa. Although minimal research exists, a handful of clinical studies found that Ibogaine and its derivatives can be used to combat addiction, and it was looked at particularly for the treatment of opioid addiction, for which the results were promising.

Unfortunately, when used at high doses over a longer period, there are potential side effects. In a recent press release, reps from MindMend explained that, “orally administered ibogaine and noribogaine present unacceptable safety risks due to their torsadogenic effects at high systemic concentrations.”

Simply put, there’s a moderate risk of heart attacks when using noribogaine. However, Dreazen believes that if the drug is administered using certain methods that better permeate the blood-brain barrier, so more of the drug actually reaches the brain rather than going to other parts of the body, including the heart. He described it as “the winning lottery ticket.”

Permeating the Blood-Brain Barrier

When it comes to treating psychological and neurological disorders, or really any other disease or condition affecting the brain, the main challenge is permeating the blood-brain barrier. The purpose of the blood-brain barrier is to protect the brain from foreign substances, and as such, can prevent up to 95% of molecules from reaching the brain.

So far, the most common way to work around that is by giving prescribing these drugs at extremely high doses, and that, needless to say, can have numerous unwanted and severe side effects. Using a more effective model, The BTLS platform, licensed from the Technion-Israel Institute of Technology, has been making use of a “liposomal vehicle with a unique targeting complex” that allows for blood-brain barrier permeation at much lower doses of various pharmaceutical agents.

This is a relatively well-known concept, but according to Dreazen, Nextage took it a step further and attached a “small arrow of seven amino acid peptides – essentially a very small protein – which is part of a much larger protein that is native to the brain and has a way of actively transporting the liposomal capsule through the blood-brain barrier. Once the capsule is drawn into the brain with the arrow, it gets lodged there and starts dissolving, facilitating release of the active material – the drug.”

What the Future Holds for Nextage

Nextage has been working in the drug delivery sector for 14 years and their daughter company, IMIO, is focused solely on psychedelics. The company completed most of required preclinical worked needed to determine the potential efficacy and generality of their new patent technology. They have already worked with CBD and THC-based medications and Nextage/IMIO plans to explore the potential of lysergic acid diethylamide (LSD).

Dreazen says LSD “is a really promising drug.” Its challenge is that when taken, people can “trip” for 15 to 17 hours, making it very unfeasible as a chronic treatment. But just like with ibogaine, he believes that if the dose can be reduced and the least amount possible gets into the body as opposed to the brain, “you could potentially get the same therapeutic effect without the longevity of the trip.”

“In the US, the psychedelic movement has exploded in the last 12 months,” Dreazen added. “I think psychedelics in Israel are just emerging, and we are the first public company to really put our teeth into it. Israel has always been in the forefront of research and development and we are committed to spearheading this industry.”

Final Thoughts

As you can see, conversations surrounding the use of psychedelics to treat mental health and neurological disorders is reaching nearly every corner of the globe, and the countries that have been more accepting of cannabis are also spearheading the medical psychedelic revelation. Psychedelics are here to stay, and in the very near future, we can expect to see a lot of these compounds being safely used in clinical and therapeutic settings.

Thank you for stopping by CBD TESTERS, your hub for all things cannabis and psychedelics-related. Make sure to Subscribe to The Delta 8 Weekly Newsletter to learn more and for exclusive deals on Delta 8Delta 10 THCTHCOTHCVTHCP & HHC.

The post Isreali Nextage Explores Effective Delivery of Psychedelic Compounds appeared first on CBD Testers.

A Win For Hemp, Agreement Is Reached in CA’s Assembly Bill 45

Assembly Bill 45 in California has long been a controversial piece of legislation, threatening to all but completely overturn the Golden State’s hemp market. However, according to the United States Hemp Roundtable, an agreement has finally been reached between hemp-industry advocates and Governor Gavin Newsom that would leave the state’s most lucrative hemp markets open and intact, should the bill pass as it’s currently written.

The cannabis industry can be complicated, and when it comes to confusing and senseless regulations, California usually takes the cake. Owning any business in California can be expensive and stressful, but if you’re working with cannabis, be prepared for some extra headaches. If you’d like to learn more about the industry, make sure to subscribe to The Medical Cannabis Weekly Newsletter. If you’re looking for exclusive deals on flowers and other products, check out our CBD Flowers Weekly NewsletterFor deals on the exotic cannabinoids, such as Delta 8Delta 10 THCTHCV, THCPTHC-O and even hemp-derived Delta-9 THC and HHC subscribe to the Delta 8 Weekly newsletter.


Is California Anti-Hemp? About Assembly Bill 45

California has always been a beacon of progressiveness; in pretty much all aspects but especially pertaining to the cannabis industry. As a matter of fact, California’s consumer marijuana market is the largest and among the least restrictive in the world. However, when it comes to hemp and CBD products, that’s a completely different ball game. California dispensaries need a special license to sell hemp flower and it’s illegal to infuse CBD in edibles, despite the fact that CBD is federally legal.

The old version of Assembly Bill 45 would have further regulated the production, distribution, and labeling of various hemp-infused products, ban hemp flowers and smokables. The California Department of Food & Agriculture would join with the state’s Bureau of Cannabis Control (BCC) to oversee the implementation of AB45, which would also outlaw CBD vapes and pens, hemp in beer, wine or spirits, and alcohol-based tinctures. In all, it would create a legislative, bureaucratic, and financial nightmare for hemp farmers, business owners, and other industry stakeholders.

“No state has sabotaged hemp as much as California,” said hemp veteran Richard Rose. “They aren’t content with killing the hemp food market for years through their legerdemain, and the birdseed market permanently,” said Rose. “They want to take CBD and smokable hemp down too.”

Furthermore, opponents of the bill claim that AB 45 is being championed almost entirely but lobbyists from competing industries who are looking to disadvantage the industrial hemp market in any way possible.

“The entire bill is crafted by outside lobbyists paid by big marijuana corporations working with HRT (the U.S. Hemp Roundtable) and the California Hemp Council, which have created a multi-million dollar bureaucracy,” said Chris Boucher, CEO at Farmtiva, a hemp ag services company and CBD consultant who also serves as a board member and treasurer at the Hemp Farmers Guild.

An Agreement Reached?

According to a written statement from the US Hemp Roundtable, the smokable hemp ban has been “replaced by a phase-in approach that will permit [its] sale to adults and the immediate manufacture of smokable products to be sold in other states.”

In this reworked bill, many of the negative facets of AB 45 would no longer apply. Various cannabinoids and hemp extracts would be permitted for use in food, beverages, dietary supplements, cosmetics, and pet food. Also, CBD flowers, vapes, and other smokeable items would not be regulated by the BCC.

It’s worth noting that Gavin Newsom is up for a recall in the state, with a vote set to take place on September 14th. That said, it makes sense that he’s backtracking various laws and bills he unsuccessfully supported and promoted in the past. The US Hemp Roundtable hopes to get a final vote on this upgraded version of AB 45 before the recall vote is underway.

Previously, the California Hemp Council had expressed its opposition to the bill, mainly because of its ban on smokable hemp/CBD flowers. The Hemp Roundtable says it coordinated with the CA Hemp Council to remove this oft-disputed provision.

Statement From The US Hemp Roundtable

“We’re excited to report that a final deal has been reached with Governor Gavin Newsom to move to final passage of AB 45, our long-term effort to explicitly permit the retail sale of hemp-derived extracts such as CBD in California. And a highlight of that compromise was the removal of language to ban hemp smokables in the state – replaced by a phase-in approach that will permit their sale to adults and the immediate manufacture of smokable products to be sold in other states.

We are deeply grateful for the leadership of Governor Gavin Newsom who met with Roundtable leadership and was deeply invested in securing passage of this bill. We are also appreciative for the leadership of the California Hemp Council, the voice of the state’s hemp industry, which partnered with the Roundtable, other California stakeholders, and, of course, our amazing bill sponsor, Rep. Cecilia Aguiar-Curry, to secure the final compromise. But mostly we are thankful to our grassroots California Hemp Supporters, who made sure that policymakers in Sacramento heard the concerns of hemp farmers, CBD businesses, and product consumers.

Of course, the battle is not yet over. While the bill has sailed through six legislative committees and the Assembly floor with only a handful of no votes, we still will have a final vote on the Senate floor next Wednesday, with one last vote on the Assembly floor next Thursday or Friday. We are asking Hemp Supporters ONE MORE TIME to head to our State Action Center to urge their state legislators to vote for this critical bill.”

The statement urges those from California to send a letter to state lawmakers supporting the reworked bill through USHR’s website.

Final Thoughts

 If everything goes according to plan, the vote on Assembly Bill 45 will take place sometime within the next week, then all it needs is a final signature from Gavin Newsom to go into effect. Check back with us for any important updates on this piece of legislation and other.

Thank you for stopping by CBD TESTERS, your hub for all things cannabis-related. And make sure to subscribe to The Medical Cannabis Weekly Newsletter for more articles like this one and exclusive deals on flowers, vape, edibles and other legal cannabis products.

The post A Win For Hemp, Agreement Is Reached in CA’s Assembly Bill 45 appeared first on CBD Testers.

A New Clinical Study To Evaluate The Effects of Cannabo-Nerve Combination On Chronic Neuropathic Pain

*** PRESS RELEASE *** San Francisco, CA – Herzliya, Israel, August 17, 2021 – Cannformatics, an early-stage biotechnology startup focused on the identification and application of saliva-based Cannabis-Responsive TM biomarkers and Cannabotech, a biomedical company developing medical solutions based on botanical combinations of cannabis extracts and functional mushrooms, today announced that Cannabotech has commissioned Cannformatics to conduct a study to evaluate the effects of Cannabotech’s Cannabo-Nerve combination on human patients suffering from chronic neuropathic pain. This study will also compare “MycoCann NeuroPain” to other leading off-the-shelf medical cannabis pain relievers that are currently being sold in the state of CA.

The CBD Testers Weekly Newsletters

“We are honored that Cannabotech chose Cannformatics to scientifically evaluate the impact of “MycoCann NeuroPain”. Pharmacometabolomic data in combination with study participant pain assessments are unique in their ability to provide insights into a product’s physiological mechanism of action and ability to manage chronic pain,” said Cannformatics CEO and Cofounder, Dr. Itzhak Kurek. “This is an exciting opportunity to support Cannabotech in bringing new hope to patients suffering with chronic neuropathic pain and deepen our understanding of pain related Cannabis-Responsive biomarkers.”

The study will be conducted under the supervision of an FDA regulated Institutional Review Board (IRB) in conjunction with Cannformatics’ Advisory Board members Dr. Donald Abrams and Dr. Bonni Goldstein. Subject to receiving IRB approval, Cannformatics will begin recruiting participants for the study. People interested in participating the study may sign up for study updates HERE.

CBD / Delta 8 / Delta 10 / THCV / THC-O Wholesale Opportunities

Elchanan Shaked, CEO and Chairman of Cannabotech, said: “For the past two-years Cannabotech has built a rigorous scientific pipeline for the development of cannabis- and mushroom-based products. The unique formulation that will be tested combines an exact composition of 13 cannabinoids and terpenes with mushroom extracts for the purpose of reducing chronic neuropathic pain without THC-related psychoactive effects. Cannformatics’ technology will provide novel insights obtained in a real-world setting, adding an important layer to the high- quality scientific evidence necessary to gain the support of the medical community ahead of a planned launching of “MycoCann NeuroPain” in the second half of 2022.”

About Cannformatics, Inc:
Cannformatics is an early-stage biotechnology startup focused on the personalization of medical cannabis treatment through the identification and application of Cannabis- Responsive biomarkers found in saliva. The company’s mission is to deliver recommendations for predictable and repeatable science-based medical cannabis treatment to improve health and quality of life. The company is now pursuing identifying Cannabis-ResponsiveTM biomarkers related to autism spectrum disorder in children.
Cannformatics is headquartered in San Francisco, CA.

About Cannabotech, Inc:
Cannabotech is an Israeli biomedical company developing botanical solutions for preventive & integrative medicine. These solutions are based on combinations of active ingredients from the cannabis plant and medicinal mushrooms focusing on two main systems in the human body: the endocannabinoid (ECS) system and the immune system. The Company’s goal is to develop products that can be integrated into existing oncology treatment protocols. Cannabotech is developing a series of eight formulas designed to help patients suffering from five cancer types (Pancreatic, Colorectal, Breast, Lung & Prostate), and minimize chemotherapy-induced chemotherapy-induced neuropathic pain (CINP) and chemotherapy-induced nausea and vomiting (CINV).
Cannabotech is headquartered in Herzliya, Israel.

*** END OF PRESS RELEASE ***

The post A New Clinical Study To Evaluate The Effects of Cannabo-Nerve Combination On Chronic Neuropathic Pain appeared first on CBD Testers.

CanBreed Introduced The World’s First Fully Stable and Genetically Uniform Cannabis Hybrid Seeds

(PRESS RELEASE): Marketing of CanBreed stable Cannabis seeds, which will enable standardization in the Cannabis industry, is expected during 2021

CanBreed, a leading Israeli Cannabis genetics and seeds company engaged in the development and enhancement of Cannabis seeds, is proud to announce that it has completed the development of the first known stable and uniform Cannabis hybrid seeds in the world. In doing so, the company brings a solution to the main problem of the Cannabis industry that suffers from lack of uniformity and standardization due to the absence of genetic stability in Cannabis plants resulting also in high production costs that hamper growers’ profits. Stable and uniform hybrid seeds, with improved genetics, are the solution to both these problems.

In June 2020, after more than three years of strenuous research and development, CanBreed completed the development of the first uniform homozygous (100% stable) Cannabis parental lines. Crosses between these parental lines creates the world’s first true F1 hybrids Cannabis seeds. The company has completed the first F1 hybrid seed production cycle in the world. These stable hybrids will ensure the reproducibility, standardization and high quality of raw material for the entire Cannabis industry.

In the present cycle, CanBreed produced dozens of stable new varieties from diverse genetic backgrounds, which will be planted for testing in CanBreed’s breeding and seeds production farm that is at its final stages of construction. At the end of the selection phase, which is expected to be completed during the first half of 2021, the seeds of the varieties that fit industry demands will be marketed.

Unlike most agricultural crops that are grown from stable seeds, Cannabis plants are presently propagated vegetatively through cloning by using cuttings from mother plants. Cloning is done in order to ensure genetic identity between the offspring and the mother plants, which until now could not be achieved by growing Cannabis from seeds because there were no stable Cannabis seeds.

The main cause of the lack of standardization that exists in the industry is that the raw material extracted from Cannabis plants grown from cuttings is not reproducible. On one hand, cloning ensures a genetic identity between the offspring and the mother plant, but on the other hand, the cloning methods that exist today (such as tissue cultures) do not prevent the aging of the mother plants. Thus, similar to the natural aging processes that take place in any living organism (including humans) mother plants accumulate aging related mutations and changes in the

genome that cause differences in the chemical profile of the plant. This leads to the fact that despite being genetically identical, the chemical profile of offspring differs from those of the young mother plants.

The reason that until now it was not possible to get reproducible and uniform Cannabis products by growing Cannabis from seeds is that all Cannabis strains in the market today are heterozygous (genetically unstable) and crossing between two unstable Cannabis strains will produce seeds with high genetic variation. Thus, today every seed grown on a plant produced from the crossing of two unstable plants is genetically different from all the other seeds on the same plant. The fact that all the seeds are different from each other in a particular Cannabis plant means that plants grown from these seeds, even though they originated from the same plant, will have a different genetic profile. Therefore, to this day, the only method available for Cannabis growers to preserve the genetic identity of the offsprings has been through cloning of mother plants.

CanBreed's genetically uniform Cannabis hybrid seeds
CanBreed’s genetically uniform Cannabis hybrid seeds

The solution to the problem comes from the seeds industry.

In the agricultural industry, plants, such as tomatoes, corn, watermelon, etc, are grown exclusively from stable seeds thus ensuring genetic uniformity that enables high quality growing and reproducibility of the products.

Stable seeds, such as tomato seeds, corn, etc. used in the agricultural industry, are produced from homozygous parental lines (plants that are 100% genetically stable). The procedure of creating homozygous plants requires dedicated resources, unique agronomic and scientific knowledge and consumes considerable time. Crossing of two different homozygous plants will produce seeds that are genetically identical, meaning that all the resultant seeds of the crossing will have the same DNA (identical twins). These seeds are known in the seed industry as F1 Hybrid seeds. Using F1 Hybrid seeds will always result in plants identical to each other, thus eliminating the need for cloning of Cannabis and Hemp and ensuring the reproducibility and uniformity of the raw material extracted from the plant.

In parallel to the development of stable seeds, CanBreed is developing YieldMaxTM, an enhanced genetic trait platform, which contains all the agronomic traits that Cannabis and Hemp growers need for consistent, high-quality, cost efficient mass-scale cultivation. The breeding of the YieldMaxTM traits is achieved by using CRISPR-Cas9, an innovative gene editing technology. Upon completion of the YieldMaxTM development, the stable seeds of CanBreed will contain also these traits.

At November, CanBreed announced that as part of its project to develop a Powdery Mildew resistance trait, which is one of the traits in the YieldMaxTM platform, the company performed and identified an editing event in the Cannabis plant genome using CRISPR-Cas9. This report follows the company’s announcement on signing a commercial license agreement for CRISPR-Cas9 foundational patents with the CRISPR patent owners – Corteva Biosciences and Broad Institute

(of MIT and Harvard). The CRISPR developers were recently awarded with the Nobel Prize in Chemistry for 2020.

The company further announced recently that it had purchased a 3.5-acre farm in San Diego county in California. A production facility of stable hemp seeds intended for the US market is planned to be set-up at the farm. The farm’s initial output is expected to be about 12.5 million seeds annually, which will subsequently increase to about 50 million seeds annually.

Ido Margalit, CanBreed CEO: “The company’s achievement comes after nearly four challenging years of development as the company faces extensive knowledge and infrastructure gaps in the field of Cannabis seeds, and in parallel invests in market education regarding the feasibility of developing stable Cannabis and Hemp seeds. CanBreed’s achievement, first of its kind in the world, positions the company at the forefront of this emerging industry that will provide a solution to a huge global potential market of Cannabis and Hemp seeds, estimated at hundreds of millions of dollars a year”.

About CanBreed

Founded in 2017, CanBreed’s goal is to increase the profitability of Cannabis farming, while enabling growers to supply uniform and high-quality raw material to Cannabis-based industries. The company is based in Israel, where the use of Medical Cannabis is legally permissible, operating one of the largest R&D Center and a seed trialing and production facility in the country. CanBreed is managed and staffed by a multidisciplinary team of dedicated seed and genetics professionals.

The post CanBreed Introduced The World’s First Fully Stable and Genetically Uniform Cannabis Hybrid Seeds appeared first on CBD Testers.

First Ever Marketplace Exclusively For Delta 8 THC Products

Introducing a first-of-its-kind marketplace for all things delta 8 THC, Direct Delta 8. Direct Delta 8 will serve as the premier online retailer for a growing array of high-quality brands and products.

Why now, why delta 8? The founders of Direct Delta 8 saw a need for a safe, reliable, and enjoyable shopping experience for consumers looking for products. Delta 8 is federally legal thanks to the 2018 Farm Bill.Advertisement

According to the bill, also known as the Agricultural Improvement Act of 2018, “All derivatives, isomers, and cannabinoids in hemp are legal provided that the final products contain less than 0.3% delta 9 THC.”

To learn more about Delta 8 and get deals on flower and other products, subscribe to the Delta 8 Weekly Newsletter


So, not only can consumers legally reap the benefits of delta 8, but they can also rest assured that they’re only getting the highest quality products. Direct Delta 8 is beginning its venture with industry leading brands such as 3Chi, Delta Effex, Skyhio, Urb Finest Flowers, and CannaAid. Users can enjoy vape cartridges that conveniently fit onto a variety of devices, or, they can choose from delta 8 edibles or tinctures.

Like CBD and cannabis itself, delta 8 as a natural therapeutic is not a new concept. Research from various sources, including the National Cancer Institute, has shown delta 8 to have positive effects. If you’re wondering how delta 8 compares to CBD and THC, it can be described as offering a calming body feeling.

While CBD offers no psychoactive effects at all, delta 8’s effects are milder than THC. Therefore, delta 8 may offer promising benefits for individuals who haven’t found relief with CBD but aren’t able to safely or legally access THC. Of course, it’s important for anyone interested in a new remedy to first consult their healthcare provider.


About Direct Delta 8:
Direct Delta 8 was founded in 2020 by a team of individuals passionate about cannabis and its derivatives. Not only does Direct Delta 8 strive to provide the highest quality products and the best customer experience, but it also wants to help people learn more about delta 8 and it’s exciting potential.

SOURCE: PR NEWSWIRE

The post First Ever Marketplace Exclusively For Delta 8 THC Products appeared first on CBD Testers.

Succesful feasibility study for the development of topical medical cannabis products

Cannassure Therapeutics Ltd (TASE: CSURE) (“Cannassure”), an Israel based developer and producer of innovative medical cannabis products, announces today the successful completion of a feasibility study for the development of IP protected, homogeneous, topical medical Cannabis products for the treatment of skin inflammation, including psoriatic lesions. (PRESS RELEASE)

To learn more about medical cannabis, subscribe to the Medical Cannabis Weekly Newsletter


Product development of such topical medical Cannabis products based on AKVANO® is being conducted under a collaboration between Cannassure and Lipidor AB (“Lipidor”), a Swedish topical drug development company, owner of the proprietary drug delivery platform technology AKVANO, which was signed in December 2019. The development project budget is partially funded by the Israeli Innovation Authority, by a non-dilutive grant.

The product under development is an incorporation of cannabinoids with AKVANO®, a topical drug delivery platform. Successful development of the product will allow localized administration of a precise dosage of cannabinoids using a spray, in a technology that allows for prolonged contact and optimal penetration of the active ingredient into the skin.

As part of the feasibility study, AKVANO® technology and cannabinoids were tested for compatibility, and it was found that the cannabinoids can be successfully combined in the AKVANO® system for a homogeneous, uniform and stable formulation. Cannassure tested the degree of product penetration into the skin by using known and acceptable models and found significant penetration of active ingredients into the skin tissue. This enhanced penetration may increase the therapeutic potential of the product. Based on these results, Cannassure will proceed to accelerated development stages and more advanced testings.

According to the agreement, Cannassure has informed Lipidor on its intention to start negotiating an exclusive global license for the use of Lipidor’s technology for the development of cannabinoids based topical therapeutics products for the treatment of indications to be chosen by Cannassure.  

The main guidelines for the licencing agreement, including royalties to be paid to Lipidor on product sales, were defined in the collaboration agreement.

According to estimates, the global market for products for the treatment of psoriasis is expected to reach 21.1 billion dollars by 2022. The current global market for topical products for the treatment of psoriasis is valued at 7 billion dollars, and the global market for topical pain treatment products is projected to reach 13 billion dollars.

The product development of topical treatments based on cannabinoids is in line with Cannassure’s strategy focused on the development and commercialisation of innovative medical cannabis products based on established drug delivery systems and formulations for enhanced therapeutic value. The product development is performed under the Israeli Medical Cannabis regulation, which allows a short development process.

About Cannassure Therapeutics Ltd.

Cannassure Therapeutics Ltd. (TASE:CSURE) is a leading, world class, trusted developer and provider of top-quality-grade medical cannabis products and pharmaceutical cannabinoid medicines, addressing a broad range of unmet medical needs.

About Lipidor AB

Lipidor AB (www.lipidor.se) is a Swedish, Stockholm-based research and development company with a pipeline of pharmaceutical development projects in preclinical and clinical phases. The Company develops topical medical products for the treatment of diseases such as psoriasis, bacterial skin infections and atopic dermatitis by reformulation of proven pharmaceutical substances.

Looking to learn more about Medical Cannabis Research? Subscribe to the Medical Cannabis Weekly newsletter.

The post Succesful feasibility study for the development of topical medical cannabis products appeared first on CBD Testers.

U.K. Regulators Launch Crackdown On CBD And Issue Health Warning

U.K. Regulators have warned the country’s CBD industry to comply with Novel Food rules or face having their products taken off their shelves.

The Food Standards Agency has also issued a health warning to mums-to- be and those taking medication not to use CBD. In a press release today the FSA has given the industry a little over a year to comply with its new novel food guidelines. 

The press release reads as follows: “The FSA has set a deadline for CBD businesses to provide more information about CBD products and their contents. It also advises vulnerable groups not to take CBD, and healthy adults to take no more than 70mg a day.

The Food Standards Agency (FSA) is giving the CBD industry a deadline of 31 March 2021 to submit valid novel food authorisation applications. After 31 March next year, only products which have submitted a valid application will be allowed to remain on the market. The authorisation process ensures novel foods meet legal standards, including on safety and content.

Keep yourself updated with the latest regulatory changes! Subscribe to the CBD Business Weekly Newsletter.

Local authorities enforce the novel food legislation. They have been advised that businesses should be able to sell their existing CBD products during this time provided they are not incorrectly labelled, are not unsafe to eat and do not contain substances that fall under drugs legislation.

In addition, the FSA is today advising those who are pregnant, breastfeeding or taking any medication not to consume CBD products. Healthy adults are also advised to think carefully before taking CBD, and the FSA recommends no more than 70mg a day (about 28 drops of 5% CBD) unless under medical direction. This new precautionary advice is based on recent findings by the government’s Committee on Toxicity (COT).

Emily Miles, Chief Executive of the Food Standards Agency, said:

“CBD products are widely available on the high street but are not properly authorised. The CBD industry must provide more information about the safety and contents of these products to the regulator before 31 March 2021, or the products will be taken off the shelves. 

The Thorny Issue Of U.K. CBD Regulation In A Post-Brexit World

Also today, we are advising that CBD could be risky for vulnerable groups, and suggesting an upper limit of 70mg a day for everyone else taking the product.

The actions that we’re taking today are a pragmatic and proportionate step in balancing the protection of public health with consumer choice. It’s now up to industry to supply this information so that the public can be reassured that CBD is safe and what it says it is.”

Professor Alan Boobis, Chair of the Committee on Toxicity, said: 

“My committee has reviewed the evidence on CBD food products and found evidence there are potential adverse health effects from the consumption of these products. We are particularly concerned about pregnant or breast-feeding women and people on medication.

“We don’t know enough to be sure about such a risk but I am pleased with the sensible and pragmatic approach the FSA is taking. The committee will continue to keep these products under review in the months ahead.”

CBD Testers will be proving reaction from the industry as we receive it. For more updates and articles like this one, subscribe to the CBD Business Weekly Newsletter.  

The post U.K. Regulators Launch Crackdown On CBD And Issue Health Warning appeared first on CBD Testers.

MJardin Group Inc. Announces Partnership with Robes Inc.

TORONTO and DENVER, Nov. 12, 2019 (GLOBE NEWSWIRE) — MJardin Group, Inc. (“MJardin” or “the Company”) (CSE: MJAR) (OTCQX: MJARF), a leader in premium cannabis production, is pleased to announce that it has entered into a partnership with Robes Inc. (“Robes”), a luxury cannabis brand house focused on bringing exotic and rare strains to Canadian consumers. Under the […]

The post MJardin Group Inc. Announces Partnership with Robes Inc. appeared first on Cannabis News | Lifestyle Tips | Expert Opinions | Stocks.

The FDA Warns Against CBD Use While Pregnant or Breastfeeding

In an October 16th statement, the FDA outlined the dangers of using cannabis products while pregnant or nursing – and that included CBD products. 

Last week, the Food and Drug Administration (FDA) made it clear that they do not condone the use of Cannbidiol (CBD) by pregnant or nursing women. Although many women prefer these natural products over prescription and OTC Medications, the FDA believes they carry “significant risk”. 

Below is a section about CBD from the report: 

“There is no comprehensive research studying the effects of CBD on the developing fetus, pregnant mother, or breastfed baby. FDA is continuing to collect and study the data on the possible harmful effects of CBD during pregnancy and while breastfeeding. However, based on what we do know, there is significant cause for concern.

High doses of CBD in pregnant test animals have caused problems with the reproductive system of developing male fetuses2 . In addition, based on what we already know about CBD, we expect that some amount of CBD will be transferred to babies through breast milk.

We also know that there is a potential for CBD products to be contaminated with substances that may pose a risk to the fetus or breastfed baby, including THC. We have also heard reports of CBD potentially containing other contaminants (e.g., pesticides, heavy metals, bacteria, and fungus); we are investigating this.

Moreover, CBD has known risks for people in general. Based on clinical studies in humans, risks can include the following:

    • liver toxicity (damage)
    • extreme sleepiness
    • harmful interactions with other drugs

FDA is studying the effects of CBD use from different angles, such as: (1) the use of CBD-containing products, like food, cosmetics, or supplements, over a person’s entire life; and (2) the effects of using these various products in combination. There are many unanswered questions about the science, safety, and quality of products containing CBD.

We especially want to learn more about the effects of CBD during pregnancy and while breastfeeding, including, for example, whether and to what extent the presence of CBD in human milk harms the breastfed baby or the mother’s milk production.”

Click here to read the full report. 

For more updates like this one, subscribe to the Medical Cannabis Weekly Newsletter. 


The post The FDA Warns Against CBD Use While Pregnant or Breastfeeding appeared first on CBD Testers.

Notice of Allowance Rewarded to SciCann Therapeutics For Its Enhanced CBD Therapy

TORONTO and TEL AVIV, Israel, Oct. 02, 2019 (GLOBE NEWSWIRE) — SciCann Therapeutics is pleased to announce that it has received a notice of allowance from the United States Patent and Trademarks Office (USPTO) for its US patent application covering the use of the proprietary SCN-002 enhanced CBD therapy for the treatment of NASH (non-alcoholic steatohepatitis).

Non-alcoholic fatty liver disease (NAFLD) is a condition in which fat builds up in the liver due to causes other than alcohol use, while non-alcoholic steatohepatitis (NASH) is a type of NAFLD in which inflammation, fibrosis and liver cell damage occur as a result of the fat deposits accumulated in the liver tissue. Several health conditions prevalent in the western society, including obesity, metabolic syndrome and type 2 diabetes, are considered as risk factors for the development of NAFLD and NASH. No medicines have yet been approved by the FDA for the treatment of these conditions.

The SCN-002 drug candidate is a novel synergistic combination of CBD and an additional botanical anti-inflammatory compound that presumably also prevents fat accumulation in the liver tissue. Pre-clinical studies performed by SciCann have demonstrated substantial synergistic effects between the two components of its proprietary SCN-002 therapy for the treatment of NASH, with a five-fold increased efficacy comparing to CBD alone, as measured by reduction of liver inflammation markers and liver enzymes elevation levels in the model animals.

SciCann is currently preparing for the launch of a double blind, randomized, placebo-controlled phase II clinical study in a leading medical center in Israel to verify the safety and efficacy of the SCN-002 product for early to mid stage NASH patients.

Dr. Zohar Koren, Co-founder and CEO of SciCann Therapeutics, stated, “NAFLD is the most common liver disorder in developed countries with an estimate of 75 to 100 million Americans suffering from the disease, while NASH, the inflammatory and fibrotic derivative of NAFLD, affects around 15 to 20 million US patients[1]. NASH might lead to complications such as cirrhosis, liver cancer, liver failure and cardiovascular disease, and is expected to become the leading cause of need for a liver transplant in the western world over the next few years.

“The fact that no therapies have yet been approved specifically for these highly prevalent indications creates a huge unmet need for novel treatments targeting liver inflammation. The positive preclinical results we have obtained so far with the SCN-002 enhanced CBD product, together with the approval by the USPTO of the US patent application covering its use for the treatment of NASH, create a solid base for the further development of this revolutionary drug candidate for NASH patients under rigorous clinical studies to be launched in Israel in the near future.” 

[1] Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, George J, Bugianesi E (January 2018). “Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention”. Nature Reviews. Gastroenterology & Hepatology. 15 (1): 11–20.

About SciCann Therapeutics
SciCann Therapeutics is a Canadian-Israeli specialty pharmaceutical company, dedicated to the development and commercialization of novel and disruptive pharmaceutical products that target and modulate the endocannabinoid system. SciCann Therapeutics is active in the fields of inflammatory disorders, oncology and neurodegenerative diseases and develops a line of proprietary cannabinoid-based products for the treatment of chosen life-threatening conditions that present a high level of unmet need.
SciCann has created a network of collaborations with leading academic centers and medical institutions in Israel in order to engage in cutting edge science and rigorous clinical studies to develop its products, while using the permissive regulatory climate in Israel for performing its R&D programs quickly and efficiently.

Original article posted by Global News Wire

For more Press Releases, subscribe to the CBD Business Weekly Newsletter.

The post Notice of Allowance Rewarded to SciCann Therapeutics For Its Enhanced CBD Therapy appeared first on CBD Testers.